JP6800757B2 - 免疫疾患の治療 - Google Patents

免疫疾患の治療 Download PDF

Info

Publication number
JP6800757B2
JP6800757B2 JP2016572424A JP2016572424A JP6800757B2 JP 6800757 B2 JP6800757 B2 JP 6800757B2 JP 2016572424 A JP2016572424 A JP 2016572424A JP 2016572424 A JP2016572424 A JP 2016572424A JP 6800757 B2 JP6800757 B2 JP 6800757B2
Authority
JP
Japan
Prior art keywords
cells
subject
ang1
cell
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016572424A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526619A5 (enExample
JP2017526619A (ja
Inventor
シルヴィウ・イテスク
ポール・シモンズ
Original Assignee
メゾブラスト・インターナショナル・エスアーエールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53385603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6800757(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2014902194A external-priority patent/AU2014902194A0/en
Application filed by メゾブラスト・インターナショナル・エスアーエールエル filed Critical メゾブラスト・インターナショナル・エスアーエールエル
Publication of JP2017526619A publication Critical patent/JP2017526619A/ja
Publication of JP2017526619A5 publication Critical patent/JP2017526619A5/ja
Application granted granted Critical
Publication of JP6800757B2 publication Critical patent/JP6800757B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2016572424A 2014-06-10 2015-06-01 免疫疾患の治療 Active JP6800757B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2014902194A AU2014902194A0 (en) 2014-06-10 Treatment of immune disorders
AUAU2014902194 2014-06-10
AUAU2014902257 2014-06-13
AU2014902257A AU2014902257A0 (en) 2014-06-13 Treatment of immune disorders 2
PCT/EP2015/062138 WO2015189063A1 (en) 2014-06-10 2015-06-01 Treatment of immune disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020195123A Division JP7009594B2 (ja) 2014-06-10 2020-11-25 免疫疾患の治療

Publications (3)

Publication Number Publication Date
JP2017526619A JP2017526619A (ja) 2017-09-14
JP2017526619A5 JP2017526619A5 (enExample) 2018-07-12
JP6800757B2 true JP6800757B2 (ja) 2020-12-16

Family

ID=53385603

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016572424A Active JP6800757B2 (ja) 2014-06-10 2015-06-01 免疫疾患の治療
JP2020195123A Active JP7009594B2 (ja) 2014-06-10 2020-11-25 免疫疾患の治療
JP2022003013A Active JP7279212B2 (ja) 2014-06-10 2022-01-12 免疫疾患の治療
JP2023077363A Active JP7680493B2 (ja) 2014-06-10 2023-05-09 免疫疾患の治療
JP2025078086A Pending JP2025109787A (ja) 2014-06-10 2025-05-08 免疫疾患の治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020195123A Active JP7009594B2 (ja) 2014-06-10 2020-11-25 免疫疾患の治療
JP2022003013A Active JP7279212B2 (ja) 2014-06-10 2022-01-12 免疫疾患の治療
JP2023077363A Active JP7680493B2 (ja) 2014-06-10 2023-05-09 免疫疾患の治療
JP2025078086A Pending JP2025109787A (ja) 2014-06-10 2025-05-08 免疫疾患の治療

Country Status (9)

Country Link
US (4) US10624930B2 (enExample)
EP (2) EP4137146A1 (enExample)
JP (5) JP6800757B2 (enExample)
KR (4) KR102704978B1 (enExample)
CN (2) CN114129598A (enExample)
AU (2) AU2015273799B2 (enExample)
CA (1) CA2950804C (enExample)
SG (1) SG11201609993YA (enExample)
WO (1) WO2015189063A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
EP2714057B1 (en) * 2011-06-03 2019-11-06 Mesoblast, Inc. Methods of treating or preventing neurological diseases
PL2785359T3 (pl) 2011-11-30 2018-12-31 Astellas Institute For Regenerative Medicine Mezenchymalne komórki zrębowe i związane z nimi zastosowania
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
WO2015189063A1 (en) 2014-06-10 2015-12-17 Mesoblast International Sàrl Treatment of immune disorders
CN106929474B (zh) * 2017-03-31 2021-09-14 北京恒峰铭成生物科技有限公司 一种m2巨噬细胞诱导剂
AU2018243554C1 (en) * 2017-03-31 2025-01-30 Wisconsin Alumni Research Foundation Generation of therapeutic cells using extracellular components of target organs
EP3716988A4 (en) 2017-11-29 2021-12-15 Figene, LLC INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR THE ACTIVATION AND USE THEREOF
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
CN112007165B (zh) * 2020-08-27 2021-10-08 北京大学人民医院 巨噬细胞极化调节剂及其在促进血小板生成中的应用
EP4630018A1 (en) * 2022-12-09 2025-10-15 Mesoblast International Sàrl Method of treating inflammation with cellular compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
CA2564679C (en) * 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
CN101103101B (zh) * 2004-09-24 2012-10-10 成血管细胞系统公司 增强间充质前体细胞（mpc）的增生和/或存活的方法
US8367405B2 (en) 2005-04-12 2013-02-05 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
WO2010005527A1 (en) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
WO2010059828A1 (en) * 2008-11-19 2010-05-27 Anthrogenesis Corporation Amnion derived adherent cells
JP5678360B2 (ja) * 2009-09-28 2015-03-04 株式会社ジーシー 間葉系幹細胞の培養方法
US20140017787A1 (en) * 2010-10-11 2014-01-16 Aline M. Betancourt Mesenchymal stem cells and related therapies
PL2785359T3 (pl) * 2011-11-30 2018-12-31 Astellas Institute For Regenerative Medicine Mezenchymalne komórki zrębowe i związane z nimi zastosowania
CN102899293A (zh) 2012-11-01 2013-01-30 上海市肺科医院 促血管生成素1基因修饰的间充质干细胞、及其构建方法与应用
KR102577698B1 (ko) * 2014-04-07 2023-09-12 메조블라스트 인터내셔널 에스에이알엘 개선된 줄기 세포 조성물
WO2015189063A1 (en) * 2014-06-10 2015-12-17 Mesoblast International Sàrl Treatment of immune disorders

Also Published As

Publication number Publication date
US12257270B2 (en) 2025-03-25
AU2020244403A1 (en) 2020-10-29
SG11201609993YA (en) 2016-12-29
US20170106023A1 (en) 2017-04-20
JP2025109787A (ja) 2025-07-25
US12616722B2 (en) 2026-05-05
JP2021028337A (ja) 2021-02-25
CN114129598A (zh) 2022-03-04
EP3154565A1 (en) 2017-04-19
AU2020244403B2 (en) 2024-03-07
US20230141347A1 (en) 2023-05-11
JP7009594B2 (ja) 2022-02-10
KR102865313B1 (ko) 2025-09-29
KR102704978B1 (ko) 2024-09-09
EP4137146A1 (en) 2023-02-22
CA2950804C (en) 2023-08-22
CN106659743B (zh) 2022-03-01
CN106659743A (zh) 2017-05-10
CA2950804A1 (en) 2015-12-17
US20200281984A1 (en) 2020-09-10
AU2015273799A1 (en) 2016-12-15
JP2023090901A (ja) 2023-06-29
KR20240135079A (ko) 2024-09-10
KR20230038590A (ko) 2023-03-20
US20250319134A1 (en) 2025-10-16
US10624930B2 (en) 2020-04-21
JP2017526619A (ja) 2017-09-14
KR20170007854A (ko) 2017-01-20
AU2015273799B2 (en) 2020-07-02
EP3154565B1 (en) 2023-05-03
KR20250143870A (ko) 2025-10-02
JP7680493B2 (ja) 2025-05-20
JP7279212B2 (ja) 2023-05-22
WO2015189063A1 (en) 2015-12-17
HK1231386A1 (en) 2017-12-22
US11406669B2 (en) 2022-08-09
JP2022040254A (ja) 2022-03-10

Similar Documents

Publication Publication Date Title
JP7009594B2 (ja) 免疫疾患の治療
JP7196216B2 (ja) 改善された幹細胞組成物
JP2025540288A (ja) 細胞組成物を用いた炎症治療方法
HK40088295A (en) Treatment of immune disorders
HK1231386B (en) Treatment of immune disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20190318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201026

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201125

R150 Certificate of patent or registration of utility model

Ref document number: 6800757

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250